Tag: anthracycline
Articles
- How to optimize your breast cancer diet
- Latest research concerning HER2 positive breast cancer prognosis
- Latest research concerning side effects of chemotherapy
- Latest research concerning triple negative breast cancer prognosis
- Latest research on factors influencing Adriamycin (doxorubicin) effectiveness
- What should BRCA1 and BRCA2 carriers, breast cancer patients and survivors eat?
- What should breast cancer patients eat during Adriamycin (doxorubicin) chemotherapy?
News
- Apigenin enhances the anticancer activity of 5-FU chemotherapy
- Bisphosphonates for treating osteoporosis may significantly reduce risk of breast cancer
- Caffeine may reduce the effectiveness of Adriamycin (doxorubicin) chemotherapy
- Chemotherapy resistance is accompanied by increase in number of breast cancer stem cells
- Cinnamon and breast cancer: the picture is unclear
- Coenzyme Q10 (CoQ10) might increase risk of postmenopausal breast cancer
- Curcumin reduces breast cancer resistance to treatment with Adriamycin (doxorubicin) chemotherapy
- Fish oil component can increase survival time for Stage IV breast cancer patients
- Garlic reduces heart damage caused by doxorubicin chemotherapy
- Grapes and other foods might help protect against Adriamycin-induced heart damage
- Herceptin has reduced locoregional recurrence for HER2+ compared to triple negative breast cancer
- Herceptin plus anthracycline chemotherapy greatly increases risk of heart damage
- Kaempferol protects against Adriamycin-induced heart damage
- Low white blood cell count as a result of chemotherapy indicates the treatment is working
- Modern chemotherapy reduces breast cancer death by about a third compared to no chemotherapy
- Non-anthracycline chemotherapy plus Herceptin is effective treatment for HER2+ breast cancer
- Outcomes of breast cancer under age 35 influenced by number of positive lymph nodes
- Possible toxic side effects of chemotherapy
- Predictors of failure to respond to neoadjuvant chemotherapy
- Response to neoadjuvant chemotherapy depends on dosage and tumor type
- Resveratrol increases effectiveness of Taxotere (docetaxel) and Adriamycin (doxorubicin)
- Selenium increases effectiveness of Taxol chemotherapy for triple negative breast cancer
- Simultaneous chemotherapy plus radiation treatment reduces breast cancer recurrence
- Taking Celebrex might reduce the effectiveness of chemotherapy for breast cancer
- Turmeric component curcumin inhibits breast cancer cell proliferation
- Very low circulating coenzyme Q10 (CoQ10) linked to increased breast cancer risk
Foods
- coffee grape seed oil green tea herring and sardines honey onions and garlic salmon tomatoes turmeric yerba maté
Studies
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- Aged Garlic Extract Protects against Doxorubicin-Induced Cardiotoxicity In Rats
- Antitumor activity of doxorubicin is enhanced by curcumin
- Apigenin augments the growth inhibitory effects of doxorubicin in breast cancer cells derived from African American patients
- Attenuation of Cytotoxic Natural Product DNA Intercalating Agents by Caffeine
- Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer
- Body mass index (BMI) and prognosis in women with metastatic breast cancer (MBC)
- BRCA2 deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure
- Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment
- Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats
- Cardiotoxic Chemotherapy is Associated with Increased Heart Failure Risk Among Women with Breast Cancer in the Cancer Research Network
- Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
- Chemotherapeutic drug effects on spontaneous mobility and swimming endurance of mice
- Chemotherapy-induced amenorrhea: Predictive markers of response to neoadjuvant chemotherapy in breast cancer
- Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies
- Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
- Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer
- Differential modulation of cisplatin and doxorubicin efficacies in leukemia cells by flavonoids
- Differential response from neoadjuvant chemotherapy across breast cancer subtypes
- Docosahexaenoic acid increases doxorubicin’s cytotoxicity against breast cancer cell lines
- Early identification of trastuzumab-related cardiotoxicity with speckle-tracking echocardiography
- Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity
- Effects of quercetin on the bioavailability of doxorubicin in rats: Role of CYP3A4 and P-gp inhibition by quercetin
- Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
- Endurance exercise protects cardiac tissue from doxorubicin-induced proteolysis and apoptosis
- Grape Seed and Skin Extract Protects Against Acute Chemotherapy Toxicity induced by Doxorubicin in Rat Heart
- Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer
- Hepatotoxicity in breast cancer patients post-chemotherapy with docetaxel, doxorubucin, and cyclophosphamide
- Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
- Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens
- Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice
- Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
- Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells
- Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro
- Late pancreatic toxicity in patients with breast cancer after taxane-anthracycline-based neoadjuvant and adjuvant chemotherapy
- Long-Term Outcomes in Stage IIIB Breast Cancer Patients Who Achieved Less Than a Pathological Complete Response After Primary Chemotherapy
- Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer
- Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission
- Pathology of late-onset anthracycline cardiomyopathy
- Patterns of Local and Distant Disease Relapse in Patients with Breast Cancer Treated with Primary Chemotherapy: Do Patients with a Complete Pathological Response Differ from Those with Residual Tumour in the Breast?
- Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in northeast china
- Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer
- Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
- Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics
- Radiation Dose and Breast Cancer Risk in the Childhood Cancer Survivor Study
- Response to influenza virus vaccination during chemotherapy in patients with breast cancer
- Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40)
- Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro
- Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles
- Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy?
- Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial
- The impact of young age on breast cancer outcome
- Tumor infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study